In this issue of Cancer, Harmsen et al have provided insight into the characteristics of BRCA1/2 mutation carriers who later develop primary peritoneal carcinoma (PPC) despite undergoing risk-reducing gynecologic surgery. 1 The authors have done a commendable job in trying to shed light on a rare condition, and this effort provides clinicians with information that can guide counseling and surveillance around risk-reducing surgery.
INTRODUCTION
In this issue of Cancer, Harmsen et al have provided insight into the characteristics of BRCA1/2 mutation carriers who later develop primary peritoneal carcinoma (PPC) despite undergoing risk-reducing gynecologic surgery. 1 The authors have done a commendable job in trying to shed light on a rare condition, and this effort provides clinicians with information that can guide counseling and surveillance around risk-reducing surgery.
Women who carry a deleterious mutation in BRCA1 or BRCA2 have a higher lifetime risk of developing ovarian cancer, cancer of the fallopian tube, and PPC. At the time of diagnosis, these gynecologic cancers tend to be high grade, of serous histology, and of advanced stage. There are no reliable screening methods available and thus these women are counseled to undergo surgical removal of the ovaries and fallopian tubes to mitigate their risk. This procedure, also known as risk-reducing salpingo-oophorectomy (RRSO), reduces the risk of gynecologic cancer development by approximately 80%. 2 The development of metachronous PPC after RRSO has been observed in 1% to 4% of women, 3, 4 but to date, there have been limited data to allow for risk stratification or an understanding of who among these women are at highest risk of this rare outcome.
The study by Harmsen et al 1 sought to address this gap in knowledge. The authors performed a Medline literature search and evaluated reference lists to identify studies reporting on cases of PPC in BRCA1/2 carriers after RRSO with no pathologic abnormalities in the ovaries or fallopian tubes. E-mail inquiries were sent to the authors of 28 relevant studies as well as to other national and international experts in the field of hereditary breast and ovarian cancer. These individuals were asked to provide information regarding cases of PPC after RRSO via a 2-page case report form that collected data concerning age, BRCA mutation status, breast cancer history (including stage of disease and tumor histology), type of risk-reducing surgery, histopathologic data, details of the peritoneal carcinoma diagnosis (including age, histology, grade, stage, and treatment), and the patient's vital status. Case report forms ultimately were retrieved from 6 authors and 2 Dutch colleagues. Six additional cases were added from the authors' own institution. This effort led to 36 evaluable cases of PPC after RRSO that occurred between 1961 and 2014, of which 8 cases could be recognized from previous publications. The initial casting of a wide net led to a modest return on effort, thereby underscoring the difficulty in putting this type of case series together. Nevertheless, this work represents a reasonably large series for a rare outcome. Among the 36 cases, the median age at the time of RRSO was 52 years, the median age at the time of PPC diagnosis was 60 years, the median interval between RRSO and PPC diagnosis was 54 months, approximately 86.1% of cases occurred in BRCA1 mutation carriers, and 6 cases had histopathologic evidence of serous tubal intraepithelial carcinoma (STIC) lesions (5 cases) or tubal epithelial atypia (1 case) in the RRSO specimen. 1 To provide a comparison group, the authors also included details from their single-institution cohort of all BRCA1/2 mutations carriers who underwent RRSO with no invasive carcinoma identified in the surgical specimen at Radboud University Medical Center in Nijmegen, the Netherlands between 2014 and 2016. As part of their institutional protocol, all specimens were completely embedded and sectioned as per the Sectioning and Extensively Examining the Fimbriated End (SEE-Fim) protocol. 5 In this comparison cohort of 113 patients, there was a lower percentage of BRCA1 mutation carriers (53.1% vs 86.1%), the median age at the time of RRSO was younger (46 years vs 52 years; P 5 .025), and the there was a lower percentage of STIC lesions in the RRSO specimens (0% vs 53.1%). Although the 36-patient PPC cohort and the more recent 113-patient RRSO group differed and were not directly comparable, Harmsen et al 1 made 3 reasonable conclusions based on their data as well as data from other published series, each of which merits discussion: 1) metachronous peritoneal carcinoma after RRSO occurs predominantly in BRCA1 mutation carriers and within 5 years of surgery; 2) surgery at a younger age lowers rates of peritoneal carcinoma; and 3) RRSO should include complete salpingectomy and detailed histopathologic examination of the specimens. Among the 36 cases of PPC after RRSO reported in this series, 31 (86.1%) occurred in BRCA1 mutation carriers and 5 (13.9%) occurred in BRCA2 mutation carriers. The median interval between RRSO and the diagnosis of PPC was 54.5 months (range, 11-292 months). 1 As the authors noted in their discussion, these findings align with those previously published by Finch et al in 2014. 4 In this international registry study, 5783 women with a BRCA1 or BRCA2 mutation were administered questionnaires and prospectively observed for the development of gynecologic cancer. A total of 32 women developed peritoneal cancer after RRSO; of those affected, 28 (87.5%) were BRCA1 mutation carriers and 4 (12.5%) were BRCA2 mutation carriers. The median time interval between RRSO and the diagnosis of PPC in this cohort was 6.1 years (range, 1-20 years). Finch et al estimated the annual risk of peritoneal cancer after RRSO was 0.20% for BRCA1 carriers and 0.10% for BRCA2 carriers. The cumulative risk of PPC in the 20 years after RRSO was estimated to be 3.9% for BRCA1 carriers and 1.9% for BRCA2 carriers. 4 The design of the current study by Harmsen et al did not allow for a calculation of the percentage of BRCA1 or BRCA2 patients in follow-up after RRSO who develop PPC because there was no denominator reflecting the larger pool of patients from which these cases arose. In the prospectively conducted study by Finch et al, 28 of 2649 BRCA1 carriers (1.05%) and 4 of 864 BRCA2 carriers (0.46%) developed subsequent metachronous PPC after RRSO. 4 Taking these 2 studies together, it is reasonable to conclude that BRCA1 carriers are at a higher risk of developing subsequent PPC compared with BRCA2 carriers (1% vs 0.5%), and that the majority of cases of PPC develop approximately 5 to 6 years after RRSO, but the range varies widely from 1 to 24 years later.
Conclusion 2: Surgery at a Younger Age Lowers Rates of Peritoneal Carcinoma
Among the 36 cases reported in the current series by Harmsen et al, the median age at the time of RRSO was 52 years (range, 30-71 years) and the median age at the time of PPC diagnosis was 60 years (range, 37-75 years). 1 The study by Finch et al did not report on the median age of the patients at the time of RRSO, but the median age at the time of diagnosis of PPC was 51.6 years (range, 36-69 years). 4 The study by Finch et al also demonstrated increasing risks of diagnosing occult carcinoma with increasing age at the time of RRSO. 4 Among BRCA1 mutation carriers, the prevalence of occult carcinoma at the time of RRSO at age <40 years was 1.5% and increased to 3.8% if surgery was performed between the ages 40 and 49 years. After age 50 years, the probability of an occult cancer diagnosis rose to 14.2%. The same trend toward an increased risk was observed for age at the time of RRSO and subsequent development of metachronous peritoneal carcinoma. Among 646 women who underwent RRSO before the age of 40 years, there were 2 cases (0.3%) of PPC, whereas among 1632 women who underwent RRSO between the ages of 40 and 50 years, there were 12 cases (0.7%). Both studies provide data to support the current recommendation for RRSO at ages 35 to 40 years for BRCA1 carriers and at ages 40 to 45 years for BRCA2 carriers. 6 The authors posit that if PPC represents the clinical manifestation of subclinical disease present at the time of RRSO, these cases theoretically can be prevented with earlier intervention. 4 This brings us to conclusion 3. The recognition that a percentage of BRCA1/2-associated "ovarian cancers" arise not from the ovaries but from the fimbriated end of the fallopian tube has led to the development of protocols such as SEE-FIM that focus on thoroughly embedding and completely examining the entire fallopian tube. 5, 7, 8 These protocols have led to the detection of noninvasive fallopian tube pathology in surgical risk-reduction specimens such as the "p53 signature" and STIC lesions. 8, 9 A diagnostic algorithm for the diagnosis of STIC has been proposed to include abnormal histologic features of the fallopian tube epithelium (such as an increased nuclear-to-cytoplasmic ratio, enlarged nuclei, prominent nucleoli, loss of polarity, and loss of ciliated cells within the context of a complete lack of stromal invasion) combined with immunohistochemical findings that support the diagnosis (p53 overexpression or null phenotype, Ki-67 overexpression). 10, 11 When protocols such as SEE-FIM are used, the detection of STIC lesions is enhanced. 12 The study by Finch et al 4 was an international registry study and did not report on the histopathologic findings from RRSO specimens. In the currently published series, 1 the finding of STIC lesions and tubal epithelial atypia in a percentage of the 36 cases most likely is the most provocative result. In the majority of cases in this series, occult preinvasive or invasive lesions very well could have been missed at the time of the original examination. Many of the surgeries were performed before the recommendation for detailed pathologic examination of the fallopian tubes was made. Inconsistencies in surgical and pathology reports made it unclear as to whether the entire fallopian tube was even completely removed in several of the cases. In fact, the entire fallopian tube was embedded and examined in only 8 of the 36 cases in the series by Harmsen et al, 1 but among these 8 cases, 5 had STIC lesions and 1 had tubal epithelial atypia. The heterogeneity in the pathologic evaluation of the original specimens makes it difficult to draw definitive conclusions, but the high rate of fallopian tube pathology in the subset of cases that underwent detailed examination certainly is interesting and lends support to the hypothesis linking preinvasive tubal lesions to a subsequent diagnosis of PPC.
When a STIC lesion is found, treatment recommendations regarding the need for surgical staging, use of adjuvant chemotherapy, and follow-up surveillance protocols differ, reflecting our incomplete understanding of the natural history of these lesions. In a cases series of 12 patients with isolated STIC lesions at the time of RRSO from Memorial Sloan Kettering Cancer Center, the shortterm clinical follow-up was reassuring. 13 Many of these patients underwent surgical staging procedures and, except for 1 case with positive peritoneal washings, no staging procedures revealed invasive or metastatic disease. All patients subsequently were observed, with no patients receiving adjuvant chemotherapy. At a median follow-up of 28 months (range, 16-44 months), there were no patients with recurrent disease. The case series further summarized the 37 additional published cases of STIC lesions at RRSO from the literature. 13 Among these 37 cases, 2 had developed subsequent PPC. A BRCA1 carrier developed PPC approximately 6 years after undergoing RRSO and an ensuing retrospective and more detailed analysis of her RRSO specimen revealed a previously undetected focus of STIC.
14 A second BRCA1 carrier underwent RRSO at the age of 49 years and developed subsequent PPC 43 months later. 13 Based on this analysis, the authors concluded that patients with STIC lesions fall into a risk category that necessitates continued surveillance that could include annual review of systems, physical examination, and serum cancer antigen 125 (CA 125) testing. 13 The current study by Harmsen et al lends further support to the recommendation for continued surveillance after RRSO in the setting of a STIC diagnosis, but the optimal surveillance regimen remains undefined.
STIC lesions are believed to represent an early precursor lesion for serous ovarian cancers, 6 and the results of the current study by Harmsen et al suggest a correlation between a STIC diagnosis and the subsequent development of PPC.
1 Metachronous PPC developed within 5 years of RRSO in approximately 66.7% of the cases in this series, 1 suggesting that premalignant tubal epithelium might shed into the peritoneal cavity before RRSO and plausibly later present as PPC, which is in keeping with a mathematical model suggesting an occult period for serous carcinoma of 5.1 years. 15 Further study will be required to determine what percentage of patients with STIC lesions ultimately develop PPC.
The National Comprehensive Cancer Network guidelines for Genetic/Familial High-Risk Assessment of Breast and Ovarian Cancer currently recommend RRSO at the time of completion of childbearing and between the ages of 35 and 40 years for BRCA1 mutation carriers and between the ages of 40 and 45 years for BRCA2 mutation carriers. 6 Despite our efforts to intervene, occult gynecologic carcinomas are found in approximately 4.5% to 9% and STIC lesions in approximately 5% to 8% of patients. 6 Furthermore, older age at the time of RRSO has been correlated with a higher incidence of STIC lesions. 16 Ideally, the goal should be to intervene with a prophylactic surgery before the development of cancerous or precancerous pathology.
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